ログイン
言語:

WEKO3

  • トップ
  • ランキング
To

Field does not validate

To

Field does not validate

To
lat lon distance


インデックスリンク

インデックスツリー

  • RootNode

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 教員研究業績
  2. 病院薬学研究室
  3. 原著論文

Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

https://gifu-pu.repo.nii.ac.jp/records/13382
https://gifu-pu.repo.nii.ac.jp/records/13382
238e52f4-9434-485e-8fab-d5f2d246a36a
Item type 研究室原著論文(1)
公開日 2018-06-18
タイトル
タイトル Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database
言語
言語 eng
キーワード
言語 en
主題Scheme Other
主題 DPP-4 inhibitors
キーワード
言語 en
主題Scheme Other
主題 Disproportionality analysis
キーワード
言語 en
主題Scheme Other
主題 Gastroesophageal reflux disease
キーワード
言語 en
主題Scheme Other
主題 Glucagon-like peptide-1 receptor agonists
キーワード
言語 en
主題Scheme Other
主題 Incretin-based drugs
キーワード
言語 en
主題Scheme Other
主題 Japanese adverse drug event report database
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
抄録
値 Background: Incretin-based drugs are important in the treatment of type 2 diabetes. However, among the incretin-based drugs, glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have been reported to cause gastroesophageal reflux disease (GERD)-like symptoms making it difficult to continue treatment. Therefore, with the aim of clarifying the relationship between incretin-based drugs and GERD-like symptoms, we conducted a pharmacoepidemiological study using the Japanese adverse drug event report database (JADER).
Methods:Dipeptidyl peptidase-4 inhibitors (DPP-4-Is) and GLP-1-RAs were set as the incretin-based target drugs. The reporting odds ratio (ROR) and the information component (IC) was used for the detection of quantitative signals. Furthermore, we also compared the time to onset of GERD-like symptoms by log-rank test.
Results:GERD-like symptoms were reported in 36 GLP-1-RAs cases (ROR: 5.61, 95% confidence interval (95% CI): 3.95-7.96 and IC: 2.17, 95% CI: 1.66-2.67) and GLP-1-RAs were detected in the signal. In contrast, DPP-4-Is were not detected in the signal.There was no sex difference with regard to the expression time of GERD-like symptoms by GLP-1-RAs (log-rank test, p = 0.5381). However, the expression time of GERD-like symptoms from GLP-1-RAs was shorter in patients older than 70 years of age than that in those younger than 70 years of age (log-rank test, p < 0.0001).
Conclusions:The administration of GLP-1-RA had a higher incidence of GERD-like symptoms earlier than the administration of DPP-4-Is. In this study, although we think that further investigation is necessary, and suggest that patients older than 70 years of age who have been administered GLP-1-RAs need earlier attention to address GERD-like symptoms than younger patients.
書誌情報 en : Journal of Pharmaceutical Health Care and Sciences

巻 4, p. 15, 発行日 2018-06-18
DOI
値 10.1186/s40780-018-0109-z
戻る
0
views
See details
Views

Versions

Ver.1 2023-06-19 08:56:21.679186
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

2018, Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database: 15– p.

Loading...

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3